Director, Ascendis Pharma A/S
TransCon modified Peptides: reprogramming pharmacokinetics of peptides by transient PEGylation
Ascendis Pharma is using its proprietary TransCon technology to engineer peptide-, protein- and antibody drugs in order to reprogram DMPK properties and safety/efficacy profiles. The TransCon technology is a traceless prodrug technology in which the pharmacokinetic profile of a drug can be fine-tuned across a very wide range. We would like to discuss examples of the technology along with Ascendis´ vision for employing the TransCon technology to make the peptide drugs of the future.